Clinical Trials Logo

Clinical Trial Summary

The study will evaluate the safety, tolerability, and immunogenicity of up to 7 different RSV vaccine candidates, some with adjuvant, when administered concomitantly with seasonal inactivated influenza vaccine (SIIV) and may evaluate a second dose of RSV vaccine administered12 months after the initial dose. In addition the study will evaluate a 2-dose regimen administered 2 months apart to 62 subjects.


Clinical Trial Description

The study will evaluate the safety, tolerability, and immunogenicity of up to 7 different RSV vaccine candidates, some with adjuvant, when administered concomitantly with SIIV. Healthy male and female subjects between 65 to 85 years of age will be enrolled. Subjects will receive 2 intramuscular injections to assess the concomitant administration of SIIV when given to subjects receiving one of the 3 RSV vaccine dose-level candidates formulated with or without an adjuvant. If interim support implementation of revaccination, invited, consenting subjects will be revaccinated with the same dose and formulation of the RSV vaccine or placebo received at Visit 1, concomitantly with SIIV. The safety, tolerability, and immunogenicity of the second dose will be evaluated through 12 months after revaccination. 62 subjects will be randomized 1:1 to receive a dose of high dose adjuvanted RSV vaccine or placebo followed by a second dose 2 months later. Safety, tolerability, and immunogenicity will be evaluated. The subjects will be enrolled before the influenza season. There will be no concomitant SIIV administration. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03572062
Study type Interventional
Source Pfizer
Contact
Status Terminated
Phase Phase 2
Start date June 5, 2018
Completion date August 19, 2020

See also
  Status Clinical Trial Phase
Completed NCT00240461 - Use of COLD-fX to Prevent Respiratory Infections in Community Dwelling Seniors Phase 3
Completed NCT03524118 - Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002) Phase 1/Phase 2
Recruiting NCT02568800 - Prolonged Infusion Cefepime and Nosocomial Infections Phase 3
Completed NCT00427141 - A Three-Part Study Of GSK580416 In Healthy Subjects Phase 1
Completed NCT04071158 - A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS Phase 2
Completed NCT00688610 - Antibiotics in Patients With Acute Respiratory Tract Infection With Procalcitonin as Parameter Phase 2
Completed NCT01549938 - Cholecalciferol Intervention to Prevent Respiratory Infections Study Phase 2
Completed NCT01789268 - Impact of Respiratory Pathogens in Infants
Completed NCT04424316 - A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy. Phase 3
Completed NCT01129765 - Home Usability of a Nasal Lavage System in Children N/A
Completed NCT01787227 - A Two Arm, Multi-Centre Clinical Evaluation of the NxTAG Respiratory Pathogen Panel N/A
Completed NCT02210156 - Effects of a Supplement on Acute Respiratory Infections N/A
Completed NCT01075204 - Clarithromycin Modified Release Observational Study for Evaluation of Treatment, Tolerability & Recovery Time in Saudi & Egyptian Clinical Settings (CLOSER) N/A
Completed NCT00585481 - Incidence of Severe Respiratory Syncytial Virus Infections in Preterm Brazilian Children N/A
Completed NCT05337163 - A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China
Completed NCT00812422 - The Efficacy and Safety of Dexibuprofen Syrup Phase 3
Active, not recruiting NCT02087761 - A Multi-Site Clinical Evaluation of the ARIES Flu Assay in Symptomatic Patients N/A
Completed NCT01076153 - Recovery Time in Thai Patients With Upper or Lower Respiratory Tract Infections Treated With Klacid MR N/A
Completed NCT00265187 - The Prevalence and Clinical Manifestations of Human Metapneumovirus Among Children With Bronchiolitis. N/A
Completed NCT04032093 - A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN Phase 2